請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17253
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟 | |
dc.contributor.author | Chin-I Hsu | en |
dc.contributor.author | 許瀞尹 | zh_TW |
dc.date.accessioned | 2021-06-08T00:03:13Z | - |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-15 | |
dc.identifier.citation | 1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
2. Weycker D, Edelsberg J, Vincze G, Levy DG, Kartashov A, Oster G. Blood pressure control in patients initiating antihypertensive therapy. The Annals of pharmacotherapy 2008;42:169-76. 3. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012;126:2105-14. 4. Su TC, Bai CH, Chang HY, et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. Journal of hypertension 2008;26:600-6. 5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA : the journal of the American Medical Association 2003;289:2560-72. 6. Wu PH, Yang CY, Yao ZL, Lin WZ, Wu LW, Chang CC. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. American journal of hypertension 2010;23:155-60. 7. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients. Circulation 2009;120:1598-605. 8. Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006;47:1039-48. 9. Chiang CE, Wang TD, Li YH, et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. Journal of the Formosan Medical Association = Taiwan yi zhi 2010;109:740-73. 10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62. 11. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA : the journal of the American Medical Association 2002;288:2981-97. 12. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. Journal of clinical hypertension (Greenwich, Conn) 2011;13:898-909. 13. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407. 14. Members WG, Roger VL, Go AS, et al. Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association. Circulation 2012;125:e2-e220. 15. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-8. 16. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57. 17. 臺灣地區高血壓、高血糖、高血脂之追蹤調查研究. 2007. (Accessed 7.5, 2013, at http://health99.doh.gov.tw/article/ArticleDetail.aspx?TopIcNo=790&DS=1-life.) 18. 行政院衛生署統計資料網. 2013. (Accessed 7.5, 2013, at http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=9510&class_no=440&level_no=1.) 19. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13. 20. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64. 21. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (Clinical research ed) 2003;326:1427. 22. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European heart journal 2007;28:1462-536. 23. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88. 24. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35. 25. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet]. . 2011 Aug. (NICE Clinical Guidelines, No. 127.). (Accessed Available from: http://www.ncbi.nlm.nih.gov/books/NBK83274/, 26. Wang TJ, Vasan RS. Epidemiology of Uncontrolled Hypertension in the United States. Circulation 2005;112:1651-62. 27. Hyman DJ, Pavlik VN. Characteristics of Patients with Uncontrolled Hypertension in the United States. New England Journal of Medicine 2001;345:479-86. 28. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate Management of Blood Pressure in a Hypertensive Population. New England Journal of Medicine 1998;339:1957-63. 29. Oliveria Sa LPMBDLIGJBDRASM. PHysician-related barriers to the effective management of uncontrolled hypertension. Archives of Internal Medicine 2002;162:413-20. 30. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. European heart journal 2011;32:2499-506. 31. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. The New England journal of medicine 2010;362:1575-85. 32. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. The American journal of medicine 2009;122:290-300. 33. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. The American journal of medicine 2011;124:128-35. 34. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. The American journal of cardiology 2000;86:1182-7. 35. Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille M-H, Duh MS. Initial Combination Therapy Reduces the Risk of Cardiovascular Events in Hypertensive Patients: A Matched Cohort Study. Hypertension 2013;61:309-18. 36. Chobanian AV. Does it matter how hypertension is controlled? The New England journal of medicine 2008;359:2485-8. 37. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The New England journal of medicine 2008;359:2417-28. 38. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. Journal of the American Society of Hypertension : JASH 2010;4:90-8. 39. Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau 2003;35:207. 40. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. Journal of human hypertension 2005;19:607-13. 41. Osterberg L, Blaschke T. Adherence to Medication. New England Journal of Medicine 2005;353:487-97. 42. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. American journal of hypertension 2006;19:1190-6. 43. Wong MCS, Tam WWS, Cheung CSK, et al. Drug adherence and the incidence of coronary heart disease- and stroke-specific mortality among 218,047 patients newly prescribed an antihypertensive medication: A five-year cohort study. International journal of cardiology. 44. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 1999;160:31-7. 45. Fitz-Simon N, Bennett K, Feely J. A review of studies of adherence with antihypertensive drugs using prescription databases. Therapeutics and clinical risk management 2005;1:93-106. 46. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. Journal of clinical hypertension (Greenwich, Conn) 2009;11:376-82. 47. Chih-Neng Hsu T-D. Secular Trends in Prescription Patterns of Single-Pill Combinations of an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Plus a Thiazide Diuretic for Hypertensive Patients in Taiwan. Acta Cardiol Sin 2013;29:49-55. 48. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53:646-53. 49. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congestive heart failure (Greenwich, Conn) 2003;9:324-32. 50. Bangalore S, Ley L. Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations. Expert opinion on pharmacotherapy 2012;13:345-55. 51. Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L. Are fixed-dose combination antihypertensives suitable as first-line therapy? Current medical research and opinion 2012;28:1685-97. 52. Angeli F, Reboldi G, Mazzotta G, et al. Fixed-dose combination therapy in hypertension: cons. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2012;19:51-4. 53. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Current medical research and opinion 2010;26:2065-76. 54. Brixner DI, Jackson KC, 2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Current medical research and opinion 2008;24:2597-607. 55. Malesker MA, Hilleman DE. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Managed care (Langhorne, Pa) 2010;19:36-42. 56. Chiou Shu-Ti CT-L, Wei Hsing-Yu. Epidemiology of Hypertension in Taiwan: The Results from a Nationwide Survey. Journal of Clinical Hypertension 2013;15:Suppl 1 :52. 57. ATC/ DDD Index 2013. WHO Collaborating Centre for Drug Statistics Methodology. (Accessed 7.4, 2013, at http://www.whocc.no/atc_ddd_index/.) 58. Sarafidis PA, Li S, Chen S-C, et al. Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease. The American journal of medicine 2008;121:332-40. 59. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75. 60. Chen W-L, Kao T-W, Wang C-C, et al. Difference of antihypertensive prescribing between office- and hospital-based clinics in Taiwan. Int J Clin Pharm 2012;34:710-8. 61. Li WW, Kuo CT, Hwang SL, Hsu HT. Factors related to medication non-adherence for patients with hypertension in Taiwan. Journal of clinical nursing 2012;21:1816-24. 62. Lee CY, Huang CC, Shih HC, Huang KH. Factors influencing antihypertensive medication compliance in Taiwan: a nationwide population-based study. European journal of preventive cardiology 2012. 63. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. The Annals of pharmacotherapy 2009;43:413-22. 64. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. The American journal of managed care 1998;4:1563-8. 65. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. International journal of clinical practice 2008;62:76-87. 66. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. Journal of hypertension 2001;19:335-41. 67. Joyce A. Cramer B, Anuja Roy M, MSc,, Anita Burrell M, et al. Medication Compliance and Persistence: Terminology and Definitions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2008;11. 68. Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. The Canadian journal of cardiology 2004;20:417-21. 69. Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. European journal of clinical pharmacology 2007;63:1055-61. 70. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2007;64:1279-83. 71. Hess G, Hill J, Lau H, Dastani H, Chaudhari P. Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy. P & T : a peer-reviewed journal for formulary management 2008;33:652-66. 72. Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence: Its Importance in Cardiovascular Outcomes. Circulation 2009;119:3028-35. 73. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. Journal of hypertension 2005;23:2093-100. 74. Schmitt KE, Edie CF, Laflam P, Simbartl LA, Thakar CV. Adherence to antihypertensive agents and blood pressure control in chronic kidney disease. American journal of nephrology 2010;32:541-8. 75. Morris AB, Li J, Kroenke K, Bruner-England TE, Young JM, Murray MD. Factors Associated with Drug Adherence and Blood Pressure Control in Patients with Hypertension. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2006;26:483-92. 76. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7. 77. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Current medical research and opinion 2008;24:121-7. 78. Lloyd-Jones DM, Leip EP, Larson MG, Vasan RS, Levy D. Novel approach to examining first cardiovascular events after hypertension onset. Hypertension 2005;45:39-45. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17253 | - |
dc.description.abstract | 研究背景
高血壓及其相關的心血管併發症至今仍為造成人類死亡的主要原因之一。雖然已有許多高血壓藥物被證實可有效控制血壓並進一步預防心血管併發症的發生,目前全球高血壓病人的血壓控制率仍相當低落。而根據臨床實證,大部分的高血壓病人可能需要合併治療的藥物療程,在這樣的考量下,多重用藥的可能性升高,進而使得病人的服藥順從性降低,造成血壓控制目標較難達到。藉由固定複方之高血壓藥物減少藥物服用顆數,預期能因此增加病人之服藥順從性。由於服藥順從性會受到病人本身的共病症、服用其他藥品種類、人種以及相關健康保險制度的影響,因此在台灣的全民健保制度下,評估固定複方劑型是否具有相關好處是值得加以探討的議題。 研究目的 利用台灣全民健康保險資料庫分析新診斷高血壓病人,使用固定複方及單方併用之高血壓用藥 (ARB+thiazide利尿劑) 在服藥順從性及藥品持續持有天數比例於兩組間是否有所不同。 研究材料與方法 本研究為一回溯性世代研究,使用臺灣全民健康保險資料庫來進行分析。研究對象為2005年至2008年間新診斷高血壓且初次使用固定複方或單方合併之ARB+thiazide利尿劑的病人。主要研究終點則由第一次開方日期往後追蹤兩年的時間,計算病人的服藥順從性及藥品持續持有天數。 服藥順從性以藥品持有率作為代表:當藥品持有率≥80%時,定義為擁有良好的服藥順從性。藥品持續持有天數則是測量病人兩年內新開方日期至停止持有藥物的開方結束日期之時間。在統計分析方面,分別利用廣義線性模型及存活分析來評估固定複方劑型相較於單方併用療法對於服藥順從性及藥品持續持有比例的影響。此外,我們也利用邏輯迴歸分析及Cox比例風險迴歸來推測除了不同的用用型態外,其他可能影響服藥順從性及藥品持續持有比例的因子。 結果 2005年至2008年間,共有7348位新診斷高血壓病人並初次開始使用固定複方(Fixed-dose combination, FDC)與單方併用(Free combination, FC)之高血壓用藥(ARB+thiazide利尿劑),其中屬於固定複方者有5725人(77.9%),單方併用者1623人(22.1%)。除了患有腎臟疾病的比例(FDC v.s. FC, 3.5% v.s. 5.2%)及新開方日期前一年內用過的高血壓藥物種類在固定複方組顯著較少外,病人大部分的基本特性在兩組間均相似。在校正過其他可能影響結果的共變項後,使用固定複方劑型的病人,相較於單方併用組,無論何種時間切點,均有較高的藥品持有率(1 year, 52.58% v.s. 46.73%, p<0.0001; 2 year, 42.06% vs. 32.45%, p<0.0001);有關於持續持有藥品,使用固定複方藥品可減低病人停止使用之風險約21% (HR 0.79, 95% CI=0.74-0.85)。新開方日期前一年使用過越多種高血壓藥物、併用降血醣藥物、新診斷六個月後方開始使用研究藥物、由醫學中心開方均為病人擁有良好服藥順從性及降低停止使用研究藥物比例的原因;罹有腎臟疾病及憂鬱症的病人則可能使服藥順從性不佳及增加停止使用藥物的風險。 結論 我們的研究發現,在兩年的追蹤時間裡,使用固定複方之高血壓用藥(ARB+thiazide利尿劑)確能增加新診斷高血壓病人的服藥順從性和藥品持續持有的人數比例。整體而言在本研究族群中,病人對於研究藥品的服藥順從性仍較為低落,我們也發現除了固定複方劑型外,其他可能影響服藥順從性的因素。本研究納入為新診斷高血壓之病人,兩年的觀察時間不足以瞭解使用固定複方者與預防相關心血管併發症發生的關聯性,因此仍需進一步臨床研究加以證實。 | zh_TW |
dc.description.abstract | Background
Until now, hypertension and its associated cardiovascular complications are still one of the major causes of death in the world. Despite many anti-hypertensive medications can prevent cardiovascular complications, the control rate of hypertension is still low around the world. Most hypertensive patients require combination therapy according to clinical evidences. Therefore, poor medication adherence would be a concern because of polypharmacy. Fixed-dose combination (FDC) is expected to improve patients’ adherence due to the decrease of pill burden. Since adherence to anti-hypertensive medications, an important factor for hypertension control, is influenced by patients’ co-morbidities, concurrent medications, ethnic populations and insurance policy, it is an important issue to investigate whether FDC has such benefit under Taiwan’s National Health Insurance (NHI) system. Objective The study aimed to compare the adherence and persistence among newly diagnosed hypertensive patients using fixed-dose combination (FDC) and free combinations (FC) of angiotensin receptor blocker (ARB)/ thiazide in Taiwan population. Materials and Methods This is a retrospective cohort study using the National Health Insurance Research Database (NHIRD) in Taiwan. Newly-diagnosed hypertensive patients who initiated FDC or FC of ARB/thiazide diuretic between 2005 and 2008 were identified from the NHIRD. Primary endpoint of our study was to analyze adherence and persistence of the study drug during 2 year follow-up. Adherence was measured by medication possession ratio (MPR) and persistence was defined as time from day of initiation to treatment discontinuation. General linear regression and Kaplan-Meier analyses were used to estimate the influence of FDC on adherence and persistence among hypertensive patients. Furthermore, we also used logistic regression model and Cox proportional hazard model to explore other predictors of adherence and persistence to study drugs. Results We identified 7348 newly-diagnosed hypertensive patients. Among them, 77.9% (n=5725) and 22.1% (n=1623) used FDC and FC of ARB/thiazide, respectively. Most demographic variables were balanced between the two groups, except for renal disease and anti-hypertensive prescriptions. After adjusting for covariates, in every different time period, patients in FDC group had higher MPR compared with FC group (1 year, 52.58% v.s. 46.73%, p<0.0001; 2 year, 42.06% vs. 32.45%, p<0.0001) and the likelihood of discontinuation of FDC therapy was significantly lower during 2-year follow-up period (HR=0.79, 95% CI=0.74-0.85). Moreover, higher adherence and lower likelihood of discontinuation of the study drug were observed in patients with previous use of anti-hypertensive therapy, anti-hyperglycemic agents, time lag between index diagnosis and index day more than 6 months, and managed at hospital center. On the contrary, having renal disease and depression increased rate of discontinuation and being low adherer. Conclusions Our findings suggest that use of FDC was associated with higher adherence and persistence rate than use of FC in newly-diagnosed hypertensive patients during 2-year follow-up period. The level of medication adherence to either FDC or FC was relative low in our study group. We also found several factors that may impact on medication adherence. However, we couldn’t conclude the potential clinical benefits associated with FDC of antihypertensive drug in newly diagnosed hypertensive patients during this 2-year follow-up period. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T00:03:13Z (GMT). No. of bitstreams: 1 ntu-102-R00451011-1.pdf: 946506 bytes, checksum: d6f77490e6ed73f68aa9b32cfafa21f2 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 致謝…… i
中文摘要 ii Abstract… iv 目錄…… vii 圖………. x 表……… xi 附錄…… xii 第1章 前言 1 第2章 文獻回顧 2 2.1 高血壓在台灣及全球之流行病學 2 2.2 高血壓之治療學 2 2.2.1 藥物治療現況 2 2.2.2 影響血壓控制不良的因子 4 2.3 合併治療於高血壓之治療地位 5 2.3.1 ARB與利尿劑之併用 6 2.4 藥品順從性 7 2.4.1 高血壓藥物之藥品順從性與心血管疾病療效之關係 7 2.4.2 影響藥物順從性之因子 8 2.5 固定複方劑型 9 2.5.1 順從性及相關醫療支出 9 2.5.2 使用的限制及考量 11 第3章 研究目的 12 第4章 研究方法 13 4.1 研究材料 13 4.2 研究設計 13 4.2.1 名詞定義 14 4.2.2 研究族群的納入與排除條件 14 4.2.3 研究終點定義 15 4.2.4 停止持有藥物後之高血壓用藥分析 15 4.3 研究資料蒐集 15 4.4 統計分析 16 4.4.1 描述性統計分析 16 4.4.2 迴歸模型分析 17 4.4.3 存活分析 17 4.4.4 統計軟體 17 第5章 研究結果 18 5.1 研究族群 18 5.1.1 病人基本資料 18 5.1.2 比較病人之基本特性 19 5.2 藥品持有率 20 5.2.1 各影響因子與藥品持有率 20 5.2.2 敏感性測試-以不同藥品持有率切點為例 23 5.3 持續持有藥品天數 23 5.3.1 各影響因子與持續持有藥品比例 23 5.3.2 停止持有藥物後之高血壓用藥分析 25 第6章 討論 26 6.1 病人基本資料 26 6.2 藥品持有率 27 6.2.1 藥品持有率與服藥順從性 28 6.2.2 良好的服藥順從性 28 6.3 持續持有藥品天數 29 6.3.1 停止持有藥物後之高血壓用藥分析 30 6.4 藥品持有率與持續持有天數之異同 30 6.5 其它影響藥品持有率與持續持有比例之因子 31 6.6 藥品持有率及持續持有天數與心血管疾病之發生率 32 6.7 本研究之研究限制與優點 33 6.7.1 研究之限制 33 6.7.2 研究之特色與優點 34 第7章 結論 35 圖……… 36 表………. 39 附錄……. 49 參考文獻 53 | |
dc.language.iso | zh-TW | |
dc.title | 新診斷高血壓病人使用固定複方與單方併用降血壓
藥物之順從性及用藥型態分析 | zh_TW |
dc.title | Adherence and Medication Utilization Patterns of Fixed-dose and Free Combination Anti-hypertensive Drugs among Newly Diagnosed Hypertensive Patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蕭斐元 | |
dc.contributor.oralexamcommittee | 林慧玲,張家勳 | |
dc.subject.keyword | 服藥順從性,合併治療,高血壓,固定複方,ARB,thiazide diuretic, | zh_TW |
dc.subject.keyword | Patient adherence,combination therapy,hypertension,fixed-dose combination,angiotensin receptor blocker,thiazide diuretic, | en |
dc.relation.page | 59 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2013-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 924.32 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。